Association of circulating levels of nicotinamide phosphoribosyltransferase (NAMPT/Visfatin) and of a frequent polymorphism in the promoter of the NAMPT gene with coronary artery disease in diabetic and non-diabetic subjects

Saddi-Rosa, Pedro; Oliveira, Carolina Soares; Crispim, Felipe; Giuffrida, Fernando MA; de Lima, Valter Correia; Vieira, José Gilberto; Doria, Alessandro; Velho, Gilberto; Reis, André Fernandes

doi:10.1186/1475-2840-12-119

Cardiovascular Diabetology

Table 2 Clinical characteristics by tertiles of plasma NAMPT and glycemic status in Brazilian cohort

From: Association of circulating levels of nicotinamide phosphoribosyltransferase (NAMPT/Visfatin) and of a frequent polymorphism in the promoter of the NAMPT gene with coronary artery disease in diabetic and non-diabetic subjects

	Subjects without type 2 diabetes			p	Type 2 diabetes subjects			p
	T1	T2	T3		T1	T2	T3
N	98	106	97		100	92	101
Plasma NAMPT(ng/ml)	3.06 ± 0.74	5.02 ± 0.56^a	8.87 ± 2.92^ab	<0.0001	3.10 ± 0.73	5.00 ± 0.50^a	8.67 ± 2.90^ab	<0.0001
Plasma NAMPT(ng/ml)	(0.57 – 4.13)	(4.14 – 6.05)	(6.08 – 19.92)	<0.0001	(0.93 – 4.13)	(4.14 – 6.03)	(6.08 – 20.18)	<0.0001
Age (y)	57 ± 10	59 ± 11	59 ± 11	0.31	59 ± 9	61 ± 10	64 ± 10^a	0.01
Sex (male)	58	58	67	0.32	46	61	51	0.11
BMI (kg/m²)	26.8 ± 4.3	25.6 ± 4.2	25.3 ± 4.4^a	0.04^c	28.5 ± 5.3	27.5 ± 4.6	28.2 ± 4.5	0.31^c
Waist circumference (cm)	97 ± 12	90 ± 14	92 ± 12	0.05^c	102 ± 12	98 ± 12	99 ± 12	0.19^c
Fasting Plasma Glucose (mmol/l)	5.6 ± 0.6	5.5 ± 0.6	5.4 ± 0.5	0.07	8.6 ± 3.7	8.1 ± 3.0	7.9 ± 2.6	0.38
HbA1c (%)	5.8 ± 0.4	5.9 ± 0.4	5.7 ± 0.4^ab	0.004	7.7 ± 1.7	7.6 ± 1.6	7.8 ± 1.8	0.78
LDL cholesterol (mmol/l)	2.77 ± 0.89	2.86 ± 0.93	2.59 ± 0.95	0.05	2.40 ± 0.79	2.58 ± 1.01	2.55 ± 0.92	0.62
HDL cholesterol (mmol/l)	0.98 ± 0.25	1.04 ± 0.28	1.01 ± 0.28	0.45	1.04 ± 0.28	0.98 ± 0.29	1.00 ± 0.30	0.29
Triglycerides (mmol/l)	1.85 ± 1.53	1.54 ± 0.69	1.38 ± 0.68^a	0.002	1.96 ± 1.22	1.94 ± 1.09	1.67 ± 0.94^a	0.05
Total adiponectin (μg/ml)	8.8 ± 6.1	10.4 ± 6.9	11.2 ± 7.8^a	0.006^c	8.4 ± 5.5	8.3 ± 8.1	8.5 ± 6.2	0.82^c
Arterial hypertension (%)	87	81	87	0.44	96	100	95	0.15
eGFR (ml/min)	87 ± 21	87 ± 25	86 ± 22	0.89	84 ± 24	82 ± 29	84 ± 28	0.56
Prevalence of CAD (%)	77	64	70	0.15	57	67	75	0.02
Antihypertensive medication (%)
ACEi	50	44	42	0.52	61	71	65	0.31
ARB	12	14	13	0.92	17	10	10	0.23
BB	41	48	40	0.47	57	52	54	0.48
Antidiabetic medication (%)
MTF	--	--	--	--	46	45	41	0.79
SU	--	--	--	--	27	22	23	0.75
INS	--	--	--	--	22	20	33	0.10

Data expressed as mean ± SD (and range, for plasma NAMPT levels). Statistics for quantitative parameters are ANOVA or ANCOVA with log-transformed data. Tukey Kramer HSD test following ANOVA/ANCOVA: significantly different (p < 0.05) from T1 (a) or T2 (b). Comparison adjusted for age and sex (c). eGFR estimated glomerular filtration rate, UAE urinary albumin excretion rate, ACEi angiotensin converting enzyme inhibitor, ARB angiotensin receptor blocker, BB beta-blocker MTF metformin, SU sulfonylurea, INS insulin.

Back to article page

ISSN: 1475-2840

Contact us

Submission enquiries: journalsubmissions@springernature.com